Table 2.
Changes in Total Cell-Associated HIV DNA Levels
| Change in HIV DNA Level From Baseline, Median (IQR) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
| Day 0 |
Day 28 |
Week 12 |
|||||||
| Dose Group | Copies/µL | Copies/106 PBMCs | Copies/106 CD4 T Cells | Log10 Copies/mL | Copies/106 PBMCs | Copies/106 CD4 T Cells | Copies/µL | Copies/106 PBMCs | Copies/106 CD4 T Cells |
| Placebo (n = 6) | 2.75 (2.62–2.98) | 2.47 (2.32–2.70) | 3.37 (3.33–3.41) | 3.02 (2.78–3.07) | 2.67 (2.68–2.79) | 3.49 (3.38–3.54) | 2.77 (2.63–2.94) | 2.51 (2.31–2.75) | 3.35 (3.09–3.58) |
| rhIL-7 dose, µg/kg | |||||||||
| 10 (n = 7) | 2.89 (2.72–3.52) | 2.63 (2.34–3.27) | 3.65 (3.16–4.15) | 3.33 (3.00–3.64) | 2.90 (2.50–3.15) | 3.57 (3.05–3.94) | 3.36 (2.89–3.48) | 3.00 (2.44–3.19) | 3.79 (3.04–3.92) |
| 20 (n = 8) | 3.52 (3.00–3.70) | 3.24 (2.87–3.36) | 4.04 (3.59–4.22) | 3.84 (3.57–4.13) | 3.38 (3.00–358) | 4.06 (3.77–4.15) | 3.63a (3.23–3.87) | 3.35 (2.87–3.40) | 3.90 (3.62–4.10) |
| 30 (n = 6) | 2.47 (2.03–3.45) | 2.29 (1.99–2.94) | 3.13 (2.62–4.03) | 3.15 (2.70–3.79) | 2.57 (2.18–3.15) | 3.16 (2.56–3.80) | 2.98a (2.64–3.69) | 2.49 (2.29–3.15) | 3.12 (2.68–3.92) |
Abbreviations: HIV, human immunodeficiency virus; IQR, interquartile range; PBMCs, peripheral blood mononuclear cells; rhIL-7, recombinant human interleukin 7.
a Increased significantly (P < .05) compared with day 0 (baseline).